A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
作者： Gunilla Enblad , Hans Hagberg , Martin Erlanson , Jeanette Lundin , Anja Porwit MacDonald
DOI: 10.1182/BLOOD-2003-10-3389
关键词:
摘要: Patients with peripheral T-cell lymphomas (PTLs) have an extremely poor prognosis when relapsed or refractory to conventional chemotherapy. We have studied alemtuzumab, a …
ashpublications.org
bloodjournal.org参考文章(23)
A. Melnyk, A. Rodriguez, W.C. Pugh, F. Cabannillas, Evaluation of the Revised European-American Lymphoma Classification Confirms the Clinical Relevance of Immunophenotype in 560 Cases of Aggressive Non-Hodgkin's Lymphoma Blood. ,vol. 89, pp. 4514- 4520 ,(1997) , 10.1182/BLOOD.V89.12.4514
MH Gilleece, TM Dexter, Effect of Campath-1H Antibody on Human Hematopoietic Progenitors In Vitro Blood. ,vol. 82, pp. 807- 812 ,(1993) , 10.1182/BLOOD.V82.3.807.807
Elaine S. Jaffe, Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues ,(2003)
Christian Gisselbrecht, Dominique Cazals-Hatem, André Bosly, Bertrand Coiffier, Luc Xerri, Eric Lepage, Hervé Tilly, Josette Brière, Reda Bouhabdallah, Corinne Haioun, Jacques Diebold, Françoise Berger, Philippe Gaulard, Prognostic Significance of T-Cell Phenotype in Aggressive Non-Hodgkin's Lymphomas Blood. ,vol. 92, pp. 76- 82 ,(1998) , 10.1182/BLOOD.V92.1.76.413A19_76_82
J Lundin, A Osterborg, G Brittinger, D Crowther, H Dombret, A Engert, A Epenetos, C Gisselbrecht, D Huhn, U Jaeger, J Thomas, R Marcus, N Nissen, C Poynton, E Rankin, R Stahel, M Uppenkamp, R Willemze, H Mellstedt, CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. ,vol. 16, pp. 3257- 3263 ,(1998) , 10.1200/JCO.1998.16.10.3257
Lia Ginaldi, Massimo De Martinis, Estella Matutes, Nahla Farahat, Ricardo Morilla, Martin J.S. Dyer, Daniel Catovsky, Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H Leukemia Research. ,vol. 22, pp. 185- 191 ,(1998) , 10.1016/S0145-2126(97)00158-6
Kritika Chaiwatanatorn, Newton Lee, Andrew Grigg, Robin Filshie, Frank Firkin, Delayed-onset neutropenia associated with rituximab therapy. British Journal of Haematology. ,vol. 121, pp. 913- 918 ,(2003) , 10.1046/J.1365-2141.2003.04385.X
J Lundin, A Porwit-MacDonald, E D Rossmann, C Karlsson, P Edman, M R Rezvany, E Kimby, A Österborg, H Mellstedt, Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia. ,vol. 18, pp. 484- 490 ,(2004) , 10.1038/SJ.LEU.2403258
J R Salisbury, N T Rapson, J D Codd, M V Rogers, A B Nethersell, Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. Journal of Clinical Pathology. ,vol. 47, pp. 313- 317 ,(1994) , 10.1136/JCP.47.4.313
Jeanette Lundin, Hans Hagberg, Roland Repp, Eva Cavallin-Ståhl, Susanne Fredén, Gunnar Juliusson, Eija Rosenblad, Geir Tjønnfjord, Tom Wiklund, Anders Österborg, Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome Blood. ,vol. 101, pp. 4267- 4272 ,(2003) , 10.1182/BLOOD-2002-09-2802